Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the company’s stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $50.02, for a total value of $92,186.86. Following the completion of the transaction, the insider now directly owns 6,371 shares in the company, valued at approximately $318,677.42. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Ventures Xi L.P. Avalon also recently made the following trade(s):
- On Monday, September 30th, Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.24, for a total value of $44,297.92.
- On Friday, September 27th, Ventures Xi L.P. Avalon sold 49,231 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.45, for a total value of $2,286,779.95.
- On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00.
- On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00.
- On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.33, for a total value of $92,364.06.
Janux Therapeutics Stock Up 0.4 %
Janux Therapeutics stock traded up $0.22 during trading hours on Friday, hitting $50.03. The stock had a trading volume of 832,354 shares, compared to its average volume of 714,847. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -43.24 and a beta of 3.54. Janux Therapeutics, Inc. has a one year low of $5.65 and a one year high of $65.60. The business’s 50 day simple moving average is $45.53 and its 200-day simple moving average is $45.30.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of JANX. Janus Henderson Group PLC lifted its holdings in Janux Therapeutics by 1.8% during the first quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after acquiring an additional 34,069 shares during the period. Vanguard Group Inc. raised its stake in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares during the period. Logos Global Management LP raised its stake in shares of Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after purchasing an additional 600,000 shares during the period. Lord Abbett & CO. LLC purchased a new position in Janux Therapeutics during the first quarter worth about $20,420,000. Finally, Samlyn Capital LLC grew its position in Janux Therapeutics by 9.6% during the second quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock worth $13,602,000 after buying an additional 28,312 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.
Analysts Set New Price Targets
Several research firms have recently issued reports on JANX. Stifel Nicolaus assumed coverage on Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research note on Monday, August 19th. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, Scotiabank reduced their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $66.13.
Check Out Our Latest Analysis on Janux Therapeutics
Janux Therapeutics Company Profile
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Read More
- Five stocks we like better than Janux Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Survey Reveals: America’s Most Coveted Businesses in 2024
- CD Calculator: Certificate of Deposit Calculator
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Why Invest in High-Yield Dividend Stocks?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.